British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
University of British Columbia, Vancouver, BC, Canada.
J Int AIDS Soc. 2021 Apr;24(4):e25699. doi: 10.1002/jia2.25699.
Treatment as prevention strategies have been variously applied across provinces in Canada. We estimated HIV care cascade indicators and correlates of unsuppressed viral load (VL) among gay, bisexual and other men who have sex with men (GBM) recruited in Vancouver, Toronto and Montreal.
Sexually active GBM, aged ≥16 years, were recruited through respondent-driven sampling (RDS) from February 2017 to August 2019. Participants completed a Computer-Assisted Self-Interview and tests for HIV and other sexually transmitted infections (STIs). We conducted bivariate analyses comparing RDS-adjusted proportions across cities. We used multivariable logistic regression to examine factors associated with having a measured VL ≥ 200 copies/mL with data pooled from all three cities.
We recruited 1179 participants in Montreal, 517 in Toronto and 753 in Vancouver. The RDS-adjusted HIV prevalence was 14.2% (95% CI 11.1 to 17.2) in Montreal, 22.1% (95% CI 12.4 to 31.8) in Toronto and 20.4% (95% CI 14.5 to 26.3) in Vancouver (p < 0.001). Of participants with confirmed HIV infection, 3.3% were previously undiagnosed in Montreal, 3.2% undiagnosed in Toronto and 0.2% in Vancouver (p = 0.154). In Montreal, 87.6% of GBM living with HIV were receiving antiretroviral therapy (ART) and 10.6% had an unsuppressed VL; in Toronto, 82.6% were receiving ART and 4.0% were unsuppressed; in Vancouver, 88.5% were receiving ART and 2.6 % were unsuppressed (p < 0.001 and 0.009 respectively). Multivariable modelling demonstrated that participants in Vancouver (adjusted odds ratio [AOR]=0.23; 95% CI 0.06 to 0.82), but not Toronto (AOR = 0.27; 95% CI 0.07 to 1.03), had lower odds of unsuppressed VL, compared to Montreal, as did older participants (AOR 0.93 per year; 95% CI 0.89 to 0.97), those at high-risk for hazardous drinking (AOR = 0.19; 95% CI 0.05 to 0.70), those with a primary care provider (AOR = 0.11; 95% CI 0.02 to 0.57), and those ever diagnosed with other STIs (AOR = 0.12; 95% CI 0.04 to 0.32).
GBM living in Montreal, Toronto and Vancouver are highly engaged in HIV testing and treatment and all three cities have largely achieved the 90-90-90 targets for GBM. Nevertheless, we identified disparities which can be used to identify GBM who may require additional interventions, in particular younger men and those who are without a regular primary care provider.
治疗即预防策略已在加拿大各省得到不同程度的应用。我们估计了温哥华、多伦多和蒙特利尔招募的男同性恋、双性恋和其他与男性发生性关系的男性(GBM)中艾滋病毒护理级联指标和未抑制病毒载量(VL)的相关因素。
从 2017 年 2 月到 2019 年 8 月,通过响应驱动抽样(RDS)招募了年龄≥16 岁、有性行为的 GBM。参与者完成了计算机辅助自我访谈以及艾滋病毒和其他性传播感染(STI)的检测。我们进行了单变量分析,比较了三个城市之间调整后的 RDS 比例。我们使用多变量逻辑回归来检查所有三个城市的数据中与测量的 VL≥200 拷贝/mL 相关的因素。
我们在蒙特利尔招募了 1179 名参与者,在多伦多招募了 517 名,在温哥华招募了 753 名。蒙特利尔、多伦多和温哥华的 RDS 调整后的 HIV 患病率分别为 14.2%(95%CI 11.1%至 17.2%)、22.1%(95%CI 12.4%至 31.8%)和 20.4%(95%CI 14.5%至 26.3%)(p<0.001)。在有确诊艾滋病毒感染的参与者中,3.3%的人在蒙特利尔以前未被诊断出,3.2%的人在多伦多未被诊断出,0.2%的人在温哥华未被诊断出(p=0.154)。在蒙特利尔,87.6%的 HIV 感染者正在接受抗逆转录病毒治疗(ART),10.6%的人 VL 未得到抑制;在多伦多,82.6%的人正在接受 ART,4.0%的人 VL 未得到抑制;在温哥华,88.5%的人正在接受 ART,2.6%的人 VL 未得到抑制(p<0.001 和 0.009 分别)。多变量模型表明,与蒙特利尔相比,温哥华(调整后的优势比 [AOR]=0.23;95%CI 0.06 至 0.82),而不是多伦多(AOR=0.27;95%CI 0.07 至 1.03),未抑制 VL 的可能性较低,年龄较大的参与者(AOR 每年 0.93;95%CI 0.89 至 0.97)、高危险饮酒的参与者(AOR=0.19;95%CI 0.05 至 0.70)、有初级保健提供者的参与者(AOR=0.11;95%CI 0.02 至 0.57)以及曾被诊断出其他性传播感染的参与者(AOR=0.12;95%CI 0.04 至 0.32)的可能性较低。
生活在蒙特利尔、多伦多和温哥华的 GBM 高度参与艾滋病毒检测和治疗,这三个城市在 GBM 中基本实现了 90-90-90 的目标。尽管如此,我们发现了一些差异,可以用来识别可能需要额外干预的 GBM,特别是年轻男性和没有定期初级保健提供者的男性。